DEENA BEASLEY,

Follow DEENA BEASLEY,: Website |


Biogen antes up another $100M to Isis Pharmaceuticals to expand collaboration

Biogen antes up another $100M to Isis Pharmaceuticals to expand collaboration

September 9, 2013 7:05 am by | 0 Comments

(Reuters) – Biogen Idec has agreed to pay another $100 million upfront to Isis Pharmaceuticals Inc as part of a broad collaboration to develop new medicines for neurological disorders, the companies said on Monday.
The deal is the fourth between the c…


Medicare probe and declining patient admissions complicate Community Health’s efforts to buy HMA

Medicare probe and declining patient admissions complicate Community Health’s efforts to buy HMA

July 19, 2013 2:41 pm by | 0 Comments

(Reuters) – A warning from hospital operator Community Health Systems Inc of declining patient admissions and news that the U.S. government is stepping up a probe of how it handles Medicare patients will complicate efforts to buy rival Health Manageme…



Medtronic’s bone growth product works as well as a traditional bone graft, but may be riskier

Medtronic’s bone growth product works as well as a traditional bone graft, but may be riskier

June 18, 2013 2:05 pm by | 0 Comments

(Reuters) – Two long-awaited independent reviews of a controversial Medtronic Inc bone growth product show it works as well as traditional bone grafts taken from patients, but it may not be as safe.
The analyses, published on Monday in the Annals of I…


Biotech stock is hot now, but what’s the prognosis?

Biotech stock is hot now, but what’s the prognosis?

May 28, 2013 7:02 am by | 0 Comments

(Reuters) – Biotech stocks are so hot that even some of the bulls are starting to find themselves on edge.
An index of biotech drugmakers’ shares has climbed nearly 50 percent in the past 12 months to all-time highs as the industry starts to launch dr…


Genetic testing is allowing a “less is more” approach to cancer treatment

Genetic testing is allowing a “less is more” approach to cancer treatment

May 15, 2013 6:54 pm by | 0 Comments

LOS ANGELES (Reuters) – After decades of using one-size-fits-all therapies to combat cancer, doctors are using new tools to help decide when their patients can skip chemotherapy or other harsh treatments.
An approach to oncology that has been in place…


Experimental Gilead drug stalls leukemia for 17 months in early trial

Experimental Gilead drug stalls leukemia for 17 months in early trial

May 15, 2013 6:12 pm by | 0 Comments

(Reuters) – An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world’s biggest seller of HIV medication…


Drugmakers face more scrutiny of discordant U.S. prices

Drugmakers face more scrutiny of discordant U.S. prices

May 10, 2013 2:26 pm by | 0 Comments

LOS ANGELES (Reuters) – The world’s biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end.
Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. pric…



J&J metal hip failed because of toxic debris – expert at trial

J&J metal hip failed because of toxic debris – expert at trial

February 1, 2013 4:47 pm by | 0 Comments

LOS ANGELES (Reuters) – Toxicity caused by debris from a metal-on-metal hip implant meant that the device had to be removed from a 66-year-old man who is suing manufacturer Johnson & Johnson, according to expert testimony heard at the trial on Fri…


Bad product vs. sick patient in first J&J hip implant trial in Los Angeles

Bad product vs. sick patient in first J&J hip implant trial in Los Angeles

January 25, 2013 6:22 pm by | 0 Comments

Los Angeles (Reuters) – Johnson & Johnson was aware of defects when it started selling its now-recalled metal hip implants in 2004, lawyers said on Friday during opening arguments in a personal injury trial against the company.
More than 10,000 la…


X and Z in favor as companies name new drugs

X and Z in favor as companies name new drugs

January 25, 2013 7:00 am by | 0 Comments

(Reuters) – They may be difficult to pronounce, but pharmaceutical companies eager to grab the attention of doctors and patients are returning to drug names starting with X and Z.
Recent X-branded names include prostate cancer treatment Xtandi, lung c…


Clinicals trial database including J&J, Lily, Merck will launch by year’s end

Clinicals trial database including J&J, Lily, Merck will launch by year’s end

November 15, 2012 9:30 am by | 0 Comments

Johnson & Johnson, Merck & Co Inc and Eli Lily & Co, plan to launch a one-stop database of global clinical trial sites aimed at streamlining paperwork and speeding the process for testing new drugs.
The partners have begun secu…


Stents, co-pays, effectiveness: Healthcare economics session added to annual meeting of heart docs

Stents, co-pays, effectiveness: Healthcare economics session added to annual meeting of heart docs

November 12, 2012 2:12 pm by | 0 Comments

LOS ANGELES (Reuters) – The cost of treating heart disease has become a key factor in decisions by U.S. cardiologists grappling with the nation’s No. 1 killer.
Record prices for drugs and devices, reduced reimbursement by insurance plans and the loomi…


Donated stem cells may work best for heart patients

Donated stem cells may work best for heart patients

November 5, 2012 7:38 pm by | 0 Comments

(Reuters) – Stem cells culled from the bone marrow of healthy donors work as well or even better as cells harvested from patients themselves as a treatment for damaged hearts and are more convenient to use, according to new research.
The 13-month tria…


Amgen experimental drug lowers cholesterol in mid-stage trial

Amgen experimental drug lowers cholesterol in mid-stage trial

November 5, 2012 1:53 pm by | 0 Comments

LOS ANGELES (Reuters) – Amgen Inc’s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial p…


Angioplasty costs are higher at non-surgery hospitals

Angioplasty costs are higher at non-surgery hospitals

November 4, 2012 10:05 pm by | 0 Comments

LOS ANGELES (Reuters) – Angioplasty to clear blocked arteries costs more at hospitals not equipped for emergency heart surgery, according to a study presented on Sunday at the American Heart Association scientific meeting.
Elective angioplasty is beco…